Melissa F. Adasme

This study systematically analyzes chemical probe literature to identify target-disease associations, revealing their utility in early therapeutic discovery and highlighting opportunities for repurposing.

This paper identifies ibrutinib as a VEGFR2 inhibitor through structure-based drug repositioning, revealing its polypharmacological action beyond BTK.

The paper evaluates drug repositioning approaches by analyzing 100 drugs, 200 targets, and 300 indications, finding that disease and target-centric methods dominate over drug-centric ones.